DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Investigator: Polly Niravath, MD

Study Coordinator: Syed Muhammad Saad

Status: Enrolling

ClinicalTrials.gov Number: NCT03734029

Phone: 281.276.5263

Protocol Number: Pro00021342

Description

The reason for this trial is to compare DS-8201a to other treatments being used for HER2-low breast cancer that has spread to other parts of the body. DS-8201a is a new medicine for breast cancer that has not been approved yet by the Food and Drug Administration. It is made of a drug and an antibody. Each participant has a 2 out of 3 chance of receiving the new medicine.
More to Explore
Live Chat Available